Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function.

Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE.

Diabetes Care. 2012 May;35(5):1119-25. doi: 10.2337/dc11-2050. Epub 2012 Mar 23.

2.

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, Turner SM, Protasio J, Riiff T, Hellerstein MK.

Diabetologia. 2012 Feb;55(2):432-42. doi: 10.1007/s00125-011-2382-3. Epub 2011 Dec 2.

PMID:
22134839
3.

Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.

Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR.

Diabetes Obes Metab. 2012 Jan;14(1):40-6. doi: 10.1111/j.1463-1326.2011.01486.x. Epub 2011 Nov 21.

5.

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.

PMID:
17909087
6.

Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.

Vega GL, Dunn FL, Grundy SM.

Am J Cardiol. 2011 Oct 15;108(8):1129-35. doi: 10.1016/j.amjcard.2011.06.011. Epub 2011 Aug 1.

PMID:
21813109
7.

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.

Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C, Zinsmeister AR, Rizza RA, Vella A.

Diabetes. 2013 Apr;62(4):1094-101. doi: 10.2337/db12-0923. Epub 2012 Dec 18.

8.

The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study.

Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S.

Metab Syndr Relat Disord. 2010 Apr;8(2):179-88. doi: 10.1089/met.2009.0049.

PMID:
20059361
9.

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75. doi: 10.1111/j.1464-5491.2008.02579.x.

PMID:
19046215
10.

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, Elisaf MS.

Metab Syndr Relat Disord. 2013 Jun;11(3):152-6. doi: 10.1089/met.2012.0103. Epub 2012 Nov 21.

PMID:
23170931
11.

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

Bays HE, Goldberg RB, Truitt KE, Jones MR.

Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.

PMID:
18852398
12.

Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.

Fujita Y, Kozawa J, Iwahashi H, Yoneda S, Uno S, Yoshikawa A, Okita K, Eguchi H, Nagano H, Imagawa A, Shimomura I.

Endocr J. 2015;62(4):329-37. doi: 10.1507/endocrj.EJ14-0456. Epub 2015 Jan 29.

13.

Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance.

Mari A, Tura A, Natali A, Laville M, Laakso M, Gabriel R, Beck-Nielsen H, Ferrannini E; RISC Investigators.

Diabetologia. 2010 Apr;53(4):749-56. Epub 2010 Jan 9.

PMID:
20225397
14.

Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.

Davidson MH, Rooney M, Pollock E, Drucker J, Choy Y.

J Clin Lipidol. 2013 Sep-Oct;7(5):423-32. doi: 10.1016/j.jacl.2013.06.001. Epub 2013 Jun 11.

PMID:
24079283
15.

Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses.

Utzschneider KM, Prigeon RL, Carr DB, Hull RL, Tong J, Shofer JB, Retzlaff BM, Knopp RH, Kahn SE.

Diabetes Care. 2006 Feb;29(2):356-62.

PMID:
16443887
16.

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.

Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L.

J Intern Med. 2013 Apr;273(4):410-21. doi: 10.1111/joim.12032. Epub 2013 Feb 14.

17.

Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.

Hung YJ, Hsieh CH, Pei D, Kuo SW, Lee JT, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.

Clin Endocrinol (Oxf). 2005 Jan;62(1):85-91.

PMID:
15638875
18.

Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

Shang Q, Saumoy M, Holst JJ, Salen G, Xu G.

Am J Physiol Gastrointest Liver Physiol. 2010 Mar;298(3):G419-24. doi: 10.1152/ajpgi.00362.2009. Epub 2009 Dec 31.

19.

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.

Muscelli E, Mari A, Natali A, Astiarraga BD, Camastra S, Frascerra S, Holst JJ, Ferrannini E.

Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1144-50. Epub 2006 Feb 14.

20.

Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.

van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M.

Diabetes Care. 2011 Apr;34(4):845-51. doi: 10.2337/dc10-2224. Epub 2011 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk